| 产品信息 |
|
| 产品名称 |
Research Grade Otilimab ( 奥替利单抗 ) Biosimilar |
| 货号 |
VAPD00073 |
| cas号 |
1638332-55-4 |
| 别名 |
|
| 靶点 |
CSF2, GM-CSF |
| 靶点登录号 |
UniProt:P04141 |
| 来源 |
293F |
| 种属 |
Human |
| 分子量 |
150kDa |
| 纯度 |
>95% |
| 缓冲液 |
PBS pH7.4 |
| 亚型 |
IgG1 |
| 内毒素 |
联系客服 |
| 性质 |
Monoclonal Antibody |
| 保存条件 |
Store at 2 to 8 °C for one week .Store at -20 to -80 °C for twelve months from the date of receipt. |
| 发货时间 |
现货3-5天 |
| 相关信息 |
见下文 |
| 提示 |
This product is for research use only,not for diagnostic or therapeutic use. |
| 其他 |
|
| 联系方式 |
18071542101 |
| 联系邮箱 |
vapolbio@163.com |
Research Grade Otilimab ( 奥替利单抗 ) Biosimilar一种抗粒细胞-巨噬细胞集落刺激因子（anti GM-CSF）单克隆抗体
-
- Rochwerg B, Agarwal A, Siemieniuk RA, et al. . A living WHO guideline on drugs for covid-19. BMJ 2020; 370: m3379. - PubMed
-
- Schulte-Schrepping J, Reusch N, Paclik D, et al. . Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell 2020; 182: 1419–1440.e1423. doi:10.1016/j.cell.2020.08.001 - DOI - PMC - PubMed
-
- Liao M, Liu Y, Yuan J, et al. . Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med 2020; 26: 842–844. doi:10.1038/s41591-020-0901-9 - DOI - PubMed
-
- Schurink B, Roos E, Radonic T, et al. . Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. Lancet Microbe 2020; 1: e290–e299. doi:10.1016/S2666-5247(20)30144-0 - DOI - PMC - PubMed
-
- Hazeldine J, Lord JM. Immunesenescence: a predisposing risk factor for the development of COVID-19? Front Immunol 2020; 11: 573662. doi:10.3389/fimmu.2020.573662 - DOI - PMC - PubMed
